|

CD70-targeted immunoPET Imaging of Malignant Cancers

RECRUITINGPhase 2Sponsored by RenJi Hospital
Actively Recruiting
PhasePhase 2
SponsorRenJi Hospital
Started2024-12-23
Est. completion2026-12-23
Eligibility
Age18 Years – 80 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06852638

Summary

This study aims to determine the value of cluster of differentiation (CD70)-targeted immuno-positron emission tomography/computed tomography (immunoPET/CT) imaging for diagnosing human malignancies, including renal cell carcinoma (particularly clear cell renal cell carcinoma), lymphoma, and nasopharyngeal carcinoma (NPC), among others.

Eligibility

Age: 18 Years – 80 YearsHealthy volunteers accepted
Inclusion Criteria:

* Aged 18-80 year-old and of either sex；
* Histologically confirmed diagnosis of renal cancer (especially ccRCC)/lymphoma/NPC or suspected renal cancer/lymphoma/NPC by diagnostic imaging;
* Capable of giving signed informed consent, including compliance with the requirements and restrictions in the informed consent form (ICF) and this protocol.

Exclusion Criteria:

* Pregnancy；
* Severe hepatic and renal insufficiency;
* Allergic to single-domain antibody radiopharmaceuticals.

Conditions8

CancerFollicular LymphomaLymphomaLymphoma, Large B-Cell, DiffuseMantle Cell LymphomaNasopharyngeal CarcinomaRenal CancerRenal Clear Cell Carcinoma

Interventions8

[18F]F-RESCA-R8B4[18F]F-RESCA-RCCB6[18F]F-RESCA-RD06[68Ga]Ga-NOTA-R8B4[68Ga]Ga-NOTA-RD06[89Zr]Zr-DFO-R8B4[89Zr]Zr-DFO-RB6[89Zr]Zr-DFO-RD06

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.